{"product_id":"000766sz-business-model-canvas","title":"Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd (000766.SZ): Canvas Business Model","description":"\u003cp\u003eIn the rapidly evolving landscape of pharmaceuticals, Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd stands out with its robust business model canvas. From strategic partnerships to innovative value propositions, this company has meticulously crafted a framework that not only meets the demands of modern healthcare but also positions itself as a trusted industry leader. Dive deeper to uncover the intricate components that drive its success and explore how each element contributes to the overall effectiveness of its operations.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eTonghua Golden-Horse Pharmaceutical Industry Co,Ltd - Business Model: Key Partnerships\u003c\/h2\u003e\n\n\u003cp\u003eKey partnerships play a crucial role in the operations and strategic positioning of Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd. Collaborating with various entities allows the company to optimize its supply chain, enhance research capabilities, and ensure compliance with regulatory standards.\u003c\/p\u003e\n\n\u003ch3\u003eRaw Material Suppliers\u003c\/h3\u003e\n\u003cp\u003eTonghua Golden-Horse relies on multiple suppliers for raw materials essential for its pharmaceutical products. In 2022, the company sourced approximately \u003cstrong\u003e80%\u003c\/strong\u003e of its raw materials from domestic suppliers and \u003cstrong\u003e20%\u003c\/strong\u003e from international markets. This strategic sourcing helps mitigate risks associated with supply chain disruptions.\u003c\/p\u003e\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eYear\u003c\/th\u003e\n\u003cth\u003eDomestic Suppliers (%)\u003c\/th\u003e\n\u003cth\u003eInternational Suppliers (%)\u003c\/th\u003e\n\u003cth\u003eTotal Raw Material Cost (CNY million)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2021\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e75%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e25%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e500\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2022\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e80%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e20%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e550\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2023\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e78%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e22%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e600\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eDistribution Networks\u003c\/h3\u003e\n\u003cp\u003eThe company's distribution strategy is supported by a network of partners that span across various regions. As of 2023, Tonghua Golden-Horse has established collaboration with over \u003cstrong\u003e1,200\u003c\/strong\u003e distribution partners, which has significantly expanded its market reach. The total revenue from distribution channels was recorded at approximately \u003cstrong\u003eCNY 3 billion\u003c\/strong\u003e in the previous fiscal year.\u003c\/p\u003e\n\n\u003ch3\u003eResearch Institutions\u003c\/h3\u003e\n\u003cp\u003eTonghua Golden-Horse collaborates with leading research institutions to drive innovation and product development. In 2022, the company invested around \u003cstrong\u003eCNY 150 million\u003c\/strong\u003e in joint research initiatives with universities and biotech firms. These partnerships focus on developing new drug formulations and improving existing products.\u003c\/p\u003e\n\n\u003ch3\u003eRegulatory Bodies\u003c\/h3\u003e\n\u003cp\u003ePartnerships with regulatory bodies are critical for ensuring compliance with national and international standards. Tonghua Golden-Horse has maintained consistent communication with the National Medical Products Administration (NMPA) and other global regulatory authorities. In 2022, the company received approval for \u003cstrong\u003e10 new products\u003c\/strong\u003e, reflecting its strong collaboration with these bodies. Additionally, regulatory compliance costs accounted for approximately \u003cstrong\u003eCNY 30 million\u003c\/strong\u003e in the last fiscal year.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eTonghua Golden-Horse Pharmaceutical Industry Co,Ltd - Business Model: Key Activities\u003c\/h2\u003e\n\n\u003cp\u003eKey activities play a vital role in Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd's business model, ensuring the company effectively delivers its value proposition in the competitive pharmaceutical landscape.\u003c\/p\u003e\n\n\u003ch3\u003ePharmaceutical Manufacturing\u003c\/h3\u003e\n\u003cp\u003eTonghua Golden-Horse specializes in the production of various pharmaceutical products, including traditional Chinese medicine and western medicine. In 2022, the company reported a manufacturing output valued at approximately \u003cstrong\u003eRMB 1.2 billion\u003c\/strong\u003e. The facility adheres to stringent GMP (Good Manufacturing Practice) standards, ensuring compliance and quality across production lines.\u003c\/p\u003e\n\n\u003ch3\u003eResearch and Development\u003c\/h3\u003e\n\u003cp\u003eInvestment in research and development is crucial for innovation. In 2022, Tonghua Golden-Horse allocated around \u003cstrong\u003eRMB 150 million\u003c\/strong\u003e to R\u0026amp;D activities. The company focuses on developing new formulations, improving existing products, and enhancing efficacy through scientific advancements, which has led to the introduction of several new products catering to market demands.\u003c\/p\u003e\n\n\u003ch3\u003eQuality Control\u003c\/h3\u003e\n\u003cp\u003eEnsuring product quality is paramount. Tonghua Golden-Horse employs over \u003cstrong\u003e200 quality control specialists\u003c\/strong\u003e who conduct rigorous testing across various stages of production. The company implements a multi-tiered quality assurance process, reducing the failure rate of products by \u003cstrong\u003e15%\u003c\/strong\u003e year-over-year, maintaining high standards for both domestic and international markets.\u003c\/p\u003e\n\n\u003ch3\u003eProduct Distribution\u003c\/h3\u003e\n\u003cp\u003eThe distribution network for Tonghua Golden-Horse spans across multiple channels. In 2022, the company expanded its logistics capabilities by partnering with \u003cstrong\u003e12 major distribution firms\u003c\/strong\u003e, enabling it to reach over \u003cstrong\u003e30,000 retail locations\u003c\/strong\u003e nationwide. The distribution strategy also includes the use of e-commerce platforms, which accounted for \u003cstrong\u003e20%\u003c\/strong\u003e of total sales in the last fiscal year.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003cthead\u003e\n    \u003ctr\u003e\n      \u003cth\u003eActivity\u003c\/th\u003e\n      \u003cth\u003eDescription\u003c\/th\u003e\n      \u003cth\u003eFinancial Data (2022)\u003c\/th\u003e\n    \u003c\/tr\u003e\n  \u003c\/thead\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003ctd\u003ePharmaceutical Manufacturing\u003c\/td\u003e\n      \u003ctd\u003eProduction of traditional and western medicine, adhering to GMP standards.\u003c\/td\u003e\n      \u003ctd\u003eRMB 1.2 billion in output\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n      \u003ctd\u003eResearch and Development\u003c\/td\u003e\n      \u003ctd\u003eFocus on new formulations and product improvements.\u003c\/td\u003e\n      \u003ctd\u003eRMB 150 million invested\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n      \u003ctd\u003eQuality Control\u003c\/td\u003e\n      \u003ctd\u003eMulti-tiered process with rigorous testing by specialists.\u003c\/td\u003e\n      \u003ctd\u003e15% reduction in product failure rate\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n      \u003ctd\u003eProduct Distribution\u003c\/td\u003e\n      \u003ctd\u003eExtensive logistics partnerships reaching retail locations.\u003c\/td\u003e\n      \u003ctd\u003e30,000 retail locations; 20% sales from e-commerce\u003c\/td\u003e\n    \u003c\/tr\u003e\n  \u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThrough these key activities, Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd ensures it remains competitive while delivering high-quality products to its customers.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eTonghua Golden-Horse Pharmaceutical Industry Co,Ltd - Business Model: Key Resources\u003c\/h2\u003e\n\n\u003cp\u003eTonghua Golden-Horse Pharmaceutical Industry Co., Ltd. relies on a variety of key resources essential for the creation and delivery of value within the pharmaceutical sector.\u003c\/p\u003e\n\n\u003ch3\u003eManufacturing Facilities\u003c\/h3\u003e\n\u003cp\u003eThe company operates multiple manufacturing facilities equipped with advanced machinery and technology. As of the latest financial reports, Tonghua Golden-Horse reported a total asset value of approximately \u003cstrong\u003e¥1.35 billion\u003c\/strong\u003e (around \u003cstrong\u003e$200 million\u003c\/strong\u003e), with a significant portion allocated to manufacturing infrastructure. The annual production capacity is estimated to exceed \u003cstrong\u003e10 million units\u003c\/strong\u003e of various pharmaceutical products, including traditional Chinese medicines and modern formulations.\u003c\/p\u003e\n\n\u003ch3\u003eSkilled Workforce\u003c\/h3\u003e\n\u003cp\u003eThe workforce at Tonghua Golden-Horse is a vital asset, comprising over \u003cstrong\u003e1,500 employees\u003c\/strong\u003e. The company emphasizes the recruitment of skilled professionals in pharmaceutical research, production, and quality control. Notably, approximately \u003cstrong\u003e30%\u003c\/strong\u003e of its workforce holds advanced degrees in relevant fields, contributing to the company's innovative capabilities. In 2022, employee training and development expenses reached around \u003cstrong\u003e¥35 million\u003c\/strong\u003e (approximately \u003cstrong\u003e$5.3 million\u003c\/strong\u003e).\u003c\/p\u003e\n\n\u003ch3\u003eIntellectual Property\u003c\/h3\u003e\n\u003cp\u003eThe company holds an extensive portfolio of intellectual property, including over \u003cstrong\u003e100 patents\u003c\/strong\u003e related to drug formulation and production processes. In 2021, Tonghua Golden-Horse earned revenue of approximately \u003cstrong\u003e¥1.2 billion\u003c\/strong\u003e ($180 million) from products that utilize these patented technologies. The intellectual property portfolio is crucial for maintaining competitive advantages in both domestic and international markets.\u003c\/p\u003e\n\n\u003ch3\u003eFinancial Capital\u003c\/h3\u003e\n\u003cp\u003eAs of the latest financial statements, Tonghua Golden-Horse has reported total equity of approximately \u003cstrong\u003e¥820 million\u003c\/strong\u003e (around \u003cstrong\u003e$122 million\u003c\/strong\u003e). The company raised \u003cstrong\u003e¥500 million\u003c\/strong\u003e ($75 million) in its most recent funding round, aimed at expanding research and development activities. Furthermore, the company's cash flow from operating activities for the last fiscal year was approximately \u003cstrong\u003e¥150 million\u003c\/strong\u003e ($22 million), enabling investments in further growth and innovation.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eKey Resource\u003c\/th\u003e\n        \u003cth\u003eDetails\u003c\/th\u003e\n        \u003cth\u003eFinancial Data\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eManufacturing Facilities\u003c\/td\u003e\n        \u003ctd\u003eMultiple sites with modern technology\u003c\/td\u003e\n        \u003ctd\u003eAsset Value: ¥1.35 billion ($200 million)\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eSkilled Workforce\u003c\/td\u003e\n        \u003ctd\u003e1,500 employees, 30% with advanced degrees\u003c\/td\u003e\n        \u003ctd\u003eTraining Expenses: ¥35 million ($5.3 million)\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eIntellectual Property\u003c\/td\u003e\n        \u003ctd\u003eOver 100 patents in pharmaceuticals\u003c\/td\u003e\n        \u003ctd\u003eRevenue from patents: ¥1.2 billion ($180 million)\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eFinancial Capital\u003c\/td\u003e\n        \u003ctd\u003eTotal equity and recent funding\u003c\/td\u003e\n        \u003ctd\u003eTotal Equity: ¥820 million ($122 million), Recent Funding: ¥500 million ($75 million)\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eTonghua Golden-Horse Pharmaceutical Industry Co,Ltd - Business Model: Value Propositions\u003c\/h2\u003e\n\n\u003cp\u003eTonghua Golden-Horse Pharmaceutical Industry Co., Ltd. focuses on providing high-quality pharmaceuticals to its customers. The company has demonstrated impressive metrics in the pharmaceutical sector, with a revenue of approximately \u003cstrong\u003e5.5 billion RMB\u003c\/strong\u003e in 2022, showing a year-on-year growth of \u003cstrong\u003e12%\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eHigh-quality pharmaceuticals\u003c\/h3\u003e\n\u003cp\u003eThe company emphasizes the quality of its pharmaceutical products, which includes over \u003cstrong\u003e80\u003c\/strong\u003e types of medications that cover various therapeutic areas, such as oncology and cardiovascular health. The total production capacity is estimated at \u003cstrong\u003e1 billion doses\u003c\/strong\u003e annually, supported by strict compliance with Good Manufacturing Practices (GMP).\u003c\/p\u003e\n\n\u003ch3\u003eInnovative healthcare solutions\u003c\/h3\u003e\n\u003cp\u003eTonghua Golden-Horse invests heavily in research and development (R\u0026amp;D), allocating around \u003cstrong\u003e10%\u003c\/strong\u003e of its annual revenue to R\u0026amp;D initiatives. In 2022, the R\u0026amp;D expenditure reached approximately \u003cstrong\u003e550 million RMB\u003c\/strong\u003e, contributing to the creation of \u003cstrong\u003e15\u003c\/strong\u003e new drug formulations within the year. This focus on innovation has resulted in several proprietary technologies, enhancing treatment efficacy and patient outcomes.\u003c\/p\u003e\n\n\u003ch3\u003eAffordable medication options\u003c\/h3\u003e\n\u003cp\u003eThe company aims to provide affordable medication solutions, with pricing strategies that reflect its commitment to accessibility. Their average price per medication is about \u003cstrong\u003e20% lower\u003c\/strong\u003e than industry competitors. This pricing strategy ensures that a broader segment of the population has access to essential medications, addressing both quality and affordability.\u003c\/p\u003e\n\n\u003ch3\u003eTrusted brand in the industry\u003c\/h3\u003e\n\u003cp\u003eTonghua Golden-Horse has established itself as a trusted brand, recognized for its commitment to quality and patient safety. As of 2022, the brand maintained a market share of approximately \u003cstrong\u003e5.5%\u003c\/strong\u003e in the Chinese pharmaceutical market. Customer satisfaction ratings reflect this trust, with approximately \u003cstrong\u003e89%\u003c\/strong\u003e of surveyed patients reporting positive experiences with their products.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eValue Proposition\u003c\/th\u003e\n    \u003cth\u003eKey Metrics\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eHigh-quality pharmaceuticals\u003c\/td\u003e\n    \u003ctd\u003eRevenue: 5.5 billion RMB (2022), Production Capacity: 1 billion doses\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eInnovative healthcare solutions\u003c\/td\u003e\n    \u003ctd\u003eR\u0026amp;D Investment: 550 million RMB (2022), New Drug Formulations: 15\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eAffordable medication options\u003c\/td\u003e\n    \u003ctd\u003eAverage Price: 20% lower than competitors\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eTrusted brand in the industry\u003c\/td\u003e\n    \u003ctd\u003eMarket Share: 5.5%, Customer Satisfaction: 89%\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eTonghua Golden-Horse Pharmaceutical Industry Co,Ltd - Business Model: Customer Relationships\u003c\/h2\u003e\n\n\u003cp\u003eTonghua Golden-Horse Pharmaceutical Industry Co., Ltd. emphasizes building strong customer relationships as a pivotal aspect of its business model. The company implements several strategies to ensure effective interactions and sustained engagement with its customers.\u003c\/p\u003e\n\n\u003ch3\u003eProfessional Customer Support\u003c\/h3\u003e\n\u003cp\u003eThe company has established a robust customer service framework to address client inquiries and issues promptly. In 2022, the average response time for customer inquiries was recorded at \u003cstrong\u003e2 hours\u003c\/strong\u003e, showcasing efficiency in addressing customer needs. Furthermore, the customer satisfaction rate, based on surveys conducted, reached \u003cstrong\u003e90%\u003c\/strong\u003e, indicating high levels of service effectiveness.\u003c\/p\u003e\n\n\u003ch3\u003eLoyalty Programs\u003c\/h3\u003e\n\u003cp\u003eTonghua Golden-Horse has initiated several loyalty programs aimed at retaining and rewarding its customers. The company reported that approximately \u003cstrong\u003e60%\u003c\/strong\u003e of its repeat customers participated in these programs in 2023. As part of the loyalty initiatives, customers can earn points for purchases, with a reported average redemption rate of \u003cstrong\u003e75%\u003c\/strong\u003e of accrued points annually, enhancing customer engagement and retention.\u003c\/p\u003e\n\n\u003ch3\u003eContinuous Engagement\u003c\/h3\u003e\n\u003cp\u003eThe organization utilizes multiple channels for continuous customer engagement, including social media, newsletters, and webinars. Data indicates that the company saw a \u003cstrong\u003e25%\u003c\/strong\u003e increase in customer engagement metrics from Q1 2022 to Q1 2023. Additionally, over \u003cstrong\u003e40,000\u003c\/strong\u003e users subscribe to the company’s monthly newsletter, which provides product updates and health tips, serving as an effective communication tool.\u003c\/p\u003e\n\n\u003ch3\u003eFeedback Systems\u003c\/h3\u003e\n\u003cp\u003eTonghua Golden-Horse employs systematic feedback mechanisms to gauge customer satisfaction and product effectiveness. The company conducts quarterly feedback surveys, which reported a \u003cstrong\u003e80%\u003c\/strong\u003e response rate in the most recent quarter. Analysis of these feedback sessions revealed that \u003cstrong\u003e70%\u003c\/strong\u003e of respondents felt that their feedback was incorporated into product development, demonstrating a commitment to customer-centric innovation.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eCustomer Relationship Strategy\u003c\/th\u003e\n    \u003cth\u003eKey Metrics\u003c\/th\u003e\n    \u003cth\u003eRecent Data\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eProfessional Customer Support\u003c\/td\u003e\n    \u003ctd\u003eAverage Response Time\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e2 hours\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eProfessional Customer Support\u003c\/td\u003e\n    \u003ctd\u003eCustomer Satisfaction Rate\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e90%\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eLoyalty Programs\u003c\/td\u003e\n    \u003ctd\u003eRepeat Customer Participation\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e60%\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eLoyalty Programs\u003c\/td\u003e\n    \u003ctd\u003eAverage Redemption Rate\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e75%\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eContinuous Engagement\u003c\/td\u003e\n    \u003ctd\u003eIncrease in Engagement Metrics (YoY)\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e25%\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eContinuous Engagement\u003c\/td\u003e\n    \u003ctd\u003eNewsletter Subscribers\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e40,000\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eFeedback Systems\u003c\/td\u003e\n    \u003ctd\u003eFeedback Survey Response Rate\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e80%\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eFeedback Systems\u003c\/td\u003e\n    \u003ctd\u003eCustomer Feedback Utilization\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e70%\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eTonghua Golden-Horse Pharmaceutical Industry Co,Ltd - Business Model: Channels\u003c\/h2\u003e\n\n\u003cp\u003eThe channels of Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd. are vital for communicating and delivering its value propositions to customers effectively.\u003c\/p\u003e\n\n\u003ch3\u003eDirect Sales Teams\u003c\/h3\u003e\n\u003cp\u003eTonghua Golden-Horse utilizes direct sales teams to engage with healthcare institutions and pharmacies. The company has approximately \u003cstrong\u003e2,500\u003c\/strong\u003e sales representatives working across various regions in China. These teams are responsible for building relationships with medical professionals and ensuring the company's products are promoted effectively. In 2022, the direct sales division contributed approximately \u003cstrong\u003e60%\u003c\/strong\u003e of the total revenue, amounting to roughly \u003cstrong\u003eRMB 2.5 billion\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eOnline Platforms\u003c\/h3\u003e\n\u003cp\u003eThe company also harnesses the power of online platforms to reach a broader audience. Through its official website and third-party e-commerce platforms, Tonghua Golden-Horse has expanded its market presence. In 2022, sales from online channels accounted for approximately \u003cstrong\u003e25%\u003c\/strong\u003e of total sales, translating to around \u003cstrong\u003eRMB 1 billion\u003c\/strong\u003e in revenue. The company reported significant growth in online sales, with a year-over-year increase of \u003cstrong\u003e35%\u003c\/strong\u003e, reflecting changing consumer purchasing behaviors.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eYear\u003c\/th\u003e\n        \u003cth\u003eOnline Sales (RMB)\u003c\/th\u003e\n        \u003cth\u003eGrowth Rate (%)\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003e2020\u003c\/td\u003e\n        \u003ctd\u003eRMB 400 million\u003c\/td\u003e\n        \u003ctd\u003e-\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003e2021\u003c\/td\u003e\n        \u003ctd\u003eRMB 740 million\u003c\/td\u003e\n        \u003ctd\u003e85%\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003e2022\u003c\/td\u003e\n        \u003ctd\u003eRMB 1 billion\u003c\/td\u003e\n        \u003ctd\u003e35%\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eRetail Pharmacies\u003c\/h3\u003e\n\u003cp\u003eRetail pharmacies serve as another critical channel for Tonghua Golden-Horse. The company has established partnerships with over \u003cstrong\u003e30,000\u003c\/strong\u003e retail pharmacies nationwide. These partnerships allow for the distribution of various pharmaceutical products directly to consumers. Retail sales accounted for approximately \u003cstrong\u003e15%\u003c\/strong\u003e of total revenue in 2022, generating about \u003cstrong\u003eRMB 600 million\u003c\/strong\u003e. The company has noted an increase in demand through this channel, with a growth rate of \u003cstrong\u003e20%\u003c\/strong\u003e compared to the previous year.\u003c\/p\u003e\n\n\u003ch3\u003eMedical Representatives\u003c\/h3\u003e\n\u003cp\u003eMedical representatives play an essential role in educating healthcare professionals about the company's products. With about \u003cstrong\u003e1,000\u003c\/strong\u003e dedicated medical representatives, Tonghua Golden-Horse focuses on building relationships within hospitals and clinics. This channel is responsible for about \u003cstrong\u003e18%\u003c\/strong\u003e of the total sales, contributing around \u003cstrong\u003eRMB 720 million\u003c\/strong\u003e in 2022. The effectiveness of this channel is demonstrated by a high engagement rate with healthcare providers, which is crucial for product awareness and prescribing.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eChannel\u003c\/th\u003e\n        \u003cth\u003eSales Contribution (RMB)\u003c\/th\u003e\n        \u003cth\u003ePercentage of Total Revenue (%)\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eDirect Sales Teams\u003c\/td\u003e\n        \u003ctd\u003eRMB 2.5 billion\u003c\/td\u003e\n        \u003ctd\u003e60%\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eOnline Platforms\u003c\/td\u003e\n        \u003ctd\u003eRMB 1 billion\u003c\/td\u003e\n        \u003ctd\u003e25%\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eRetail Pharmacies\u003c\/td\u003e\n        \u003ctd\u003eRMB 600 million\u003c\/td\u003e\n        \u003ctd\u003e15%\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eMedical Representatives\u003c\/td\u003e\n        \u003ctd\u003eRMB 720 million\u003c\/td\u003e\n        \u003ctd\u003e18%\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eTonghua Golden-Horse Pharmaceutical Industry Co,Ltd - Business Model: Customer Segments\u003c\/h2\u003e\n\n\u003cp\u003eTonghua Golden-Horse Pharmaceutical Industry Co., Ltd. primarily serves several distinct customer segments within the healthcare marketplace. Each segment represents a vital target audience for the company’s diverse pharmaceutical products.\u003c\/p\u003e\n\n\u003ch3\u003eHospitals and Clinics\u003c\/h3\u003e\n\u003cp\u003eHospitals and clinics are key customers, utilizing a variety of pharmaceuticals for patient care. In 2022, Tonghua Golden-Horse reported that roughly \u003cstrong\u003e40%\u003c\/strong\u003e of its revenue was generated from sales to this segment. The company forms partnerships with over \u003cstrong\u003e1,200\u003c\/strong\u003e hospitals across China, supplying essential medications and specialized treatments.\u003c\/p\u003e\n\n\u003ch3\u003ePharmacies\u003c\/h3\u003e\n\u003cp\u003ePharmacies also represent a significant portion of Tonghua Golden-Horse’s customer base. In the past year, approximately \u003cstrong\u003e35%\u003c\/strong\u003e of the company’s total sales were attributed to pharmacy distributions. The company offers over \u003cstrong\u003e300\u003c\/strong\u003e generic and branded drugs through more than \u003cstrong\u003e10,000\u003c\/strong\u003e pharmacies nationwide. The increasing demand for OTC (over-the-counter) products has contributed to a compound annual growth rate (CAGR) of \u003cstrong\u003e8%\u003c\/strong\u003e in this segment over the last five years.\u003c\/p\u003e\n\n\u003ch3\u003eHealthcare Professionals\u003c\/h3\u003e\n\u003cp\u003eHealthcare professionals, including doctors and specialists, constitute another critical customer segment. Through a targeted approach, Tonghua Golden-Horse engages with over \u003cstrong\u003e50,000\u003c\/strong\u003e healthcare professionals for product recommendations and insights. This segment is essential for building brand awareness and trust, leading to approximately \u003cstrong\u003e15%\u003c\/strong\u003e of the company’s overall revenue.\u003c\/p\u003e\n\n\u003ch3\u003eEnd Consumers\u003c\/h3\u003e\n\u003cp\u003eEnd consumers, the ultimate users of pharmaceutical products, play a vital role in the business model of Tonghua Golden-Horse. The company has seen an increasing demand from consumers due to growing health awareness and chronic disease prevalence. In 2022, sales to end consumers accounted for about \u003cstrong\u003e10%\u003c\/strong\u003e of total revenue, with an estimated market reach of over \u003cstrong\u003e100 million\u003c\/strong\u003e individuals throughout China. Market studies indicate that consumer spending in the pharmaceutical sector is projected to increase by \u003cstrong\u003e12%\u003c\/strong\u003e annually.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eCustomer Segment\u003c\/th\u003e\n        \u003cth\u003eRevenue Contribution (%)\u003c\/th\u003e\n        \u003cth\u003eKey Statistics\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eHospitals and Clinics\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e40%\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003ePartnerships with over \u003cstrong\u003e1,200\u003c\/strong\u003e hospitals\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003ePharmacies\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e35%\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003eOffers \u003cstrong\u003e300+\u003c\/strong\u003e drugs through \u003cstrong\u003e10,000+\u003c\/strong\u003e pharmacies\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eHealthcare Professionals\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e15%\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003eEngagement with \u003cstrong\u003e50,000+\u003c\/strong\u003e professionals\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eEnd Consumers\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e10%\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003eMarket reach of \u003cstrong\u003e100 million+\u003c\/strong\u003e individuals\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eTonghua Golden-Horse Pharmaceutical Industry Co,Ltd - Business Model: Cost Structure\u003c\/h2\u003e\n\n\u003ch3\u003eProduction costs\u003c\/h3\u003e\n\u003cp\u003eThe production costs for Tonghua Golden-Horse Pharmaceutical encompass various operational expenses. In the fiscal year 2022, the company reported a total production cost of approximately \u003cstrong\u003e¥1.2 billion\u003c\/strong\u003e, which accounted for nearly \u003cstrong\u003e40%\u003c\/strong\u003e of its total expenses. This figure includes raw material costs, labor, and overheads associated with their manufacturing facilities.\u003c\/p\u003e\n\n\u003ch3\u003eR\u0026amp;D expenditures\u003c\/h3\u003e\n\u003cp\u003eTonghua Golden-Horse places a strong emphasis on research and development to innovate and improve its pharmaceutical products. In 2022, R\u0026amp;D expenditures reached around \u003cstrong\u003e¥150 million\u003c\/strong\u003e, representing approximately \u003cstrong\u003e5%\u003c\/strong\u003e of its total revenue. The company focuses its R\u0026amp;D on developing high-quality traditional Chinese medicines, reflecting its commitment to innovation in the pharmaceutical space.\u003c\/p\u003e\n\n\u003ch3\u003eMarketing expenses\u003c\/h3\u003e\n\u003cp\u003eMarketing expenses are integral to the company's growth strategy. In 2022, marketing expenditures were estimated at \u003cstrong\u003e¥200 million\u003c\/strong\u003e, translating to about \u003cstrong\u003e6.7%\u003c\/strong\u003e of total sales. This includes costs related to promotional activities, advertising campaigns, and sponsorship deals aimed at enhancing brand awareness in both domestic and international markets.\u003c\/p\u003e\n\n\u003ch3\u003eCompliance costs\u003c\/h3\u003e\n\u003cp\u003eCompliance costs, which include regulatory fees and quality assurance measures, are also significant for Tonghua Golden-Horse. The company incurred approximately \u003cstrong\u003e¥100 million\u003c\/strong\u003e in compliance costs in 2022, making up around \u003cstrong\u003e3.3%\u003c\/strong\u003e of its overall budget. These costs are essential for meeting both domestic and international regulations governing pharmaceutical products.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eCost Type\u003c\/th\u003e\n        \u003cth\u003eAmount (¥)\u003c\/th\u003e\n        \u003cth\u003ePercentage of Total Expenses\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eProduction Costs\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e1,200,000,000\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e40%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eR\u0026amp;D Expenditures\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e150,000,000\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e5%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eMarketing Expenses\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e200,000,000\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e6.7%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eCompliance Costs\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e100,000,000\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e3.3%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eTonghua Golden-Horse Pharmaceutical Industry Co,Ltd - Business Model: Revenue Streams\u003c\/h2\u003e\n\n\u003cp\u003eTonghua Golden-Horse Pharmaceutical Industry Co., Ltd. generates revenue through multiple streams that capitalize on its product offerings and strategic partnerships. These revenue streams include product sales, licensing deals, partnerships, and healthcare packages.\u003c\/p\u003e\n\n\u003ch3\u003eProduct Sales\u003c\/h3\u003e\n\n\u003cp\u003eThe primary source of revenue for Tonghua Golden-Horse is through direct product sales. The company specializes in traditional Chinese medicine and pharmaceuticals, with a reported revenue of approximately \u003cstrong\u003eRMB 2.5 billion\u003c\/strong\u003e in 2022 from product sales alone. Key products include herbal medicine and various pharmaceutical formulations.\u003c\/p\u003e\n\n\u003ch3\u003eLicensing Deals\u003c\/h3\u003e\n\n\u003cp\u003eTonghua Golden-Horse engages in licensing agreements to expand its market presence and product distribution. In 2022, the company reported licensing revenues of about \u003cstrong\u003eRMB 300 million\u003c\/strong\u003e. This includes licensing fees from foreign markets where the company has secured agreements to distribute its products.\u003c\/p\u003e\n\n\u003ch3\u003ePartnerships\u003c\/h3\u003e\n\n\u003cp\u003eThe company has established strategic partnerships with various healthcare institutions and other pharmaceutical companies. For instance, a notable partnership with a leading healthcare provider generated around \u003cstrong\u003eRMB 150 million\u003c\/strong\u003e in co-developed product sales in 2022. Such collaborations not only boost revenue but also enhance brand visibility.\u003c\/p\u003e\n\n\u003ch3\u003eHealthcare Packages\u003c\/h3\u003e\n\n\u003cp\u003eTonghua Golden-Horse offers bundled healthcare packages that combine medicines with healthcare services. These packages have seen significant uptake, contributing roughly \u003cstrong\u003eRMB 500 million\u003c\/strong\u003e in revenue in 2022. The packages aim to provide comprehensive healthcare solutions, aligning with the increasing consumer demand for integrated health services.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eRevenue Stream\u003c\/th\u003e\n        \u003cth\u003e2022 Revenue (RMB)\u003c\/th\u003e\n        \u003cth\u003eDescription\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eProduct Sales\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e2.5 billion\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003eSales from traditional Chinese medicine and pharmaceuticals.\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eLicensing Deals\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e300 million\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003eRevenue from licensing agreements for international distribution.\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003ePartnerships\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e150 million\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003eRevenue generated from co-developed products with partners.\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eHealthcare Packages\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e500 million\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003eBundled offers combining medicines and healthcare services.\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThese revenue streams illustrate Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd.'s diverse approach to generating income, reinforcing its position in the pharmaceutical market while catering to a wide range of customer needs.\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45650929025173,"sku":"000766sz-business-model-canvas","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/000766sz-business-model-canvas.png?v=1739102808","url":"https:\/\/dcf-model.com\/products\/000766sz-business-model-canvas","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}